Document is current
Any future updates will be listed below
-
Authors
Yu, Jeffrey
Kielhorn, Adrian
Murdoch, James
Martin, Marcus
Martin, Eddilisa
McNeil-Posey, Kelly
Mungin, Barbara
Xia, Yiyi
Erler, Wendy
Kurukulasuriya, Nuwan C.
-
Funding
Funding for this research was provided by:
Alexion Pharmaceuticals
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 10 February 2025
First Online: 3 March 2025
Declarations
:
: Adrian Kielhorn, Jeffrey Yu, Kelly McNeil-Posey, Barbara Mungin, Yiyi Xia, Wendy Erler, and Nuwan C. Kurukulasuriya are employees of Alexion, AstraZeneca Rare Disease, the study sponsor. James Murdoch, Eddilisa Martin, and Marcus Martin received payment from Alexion, AstraZeneca Rare Disease to assist with the design and conduct of the study.
: The study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments, and all study participants provided informed written consent. The REMADE study was granted a waiver from ethics committee approval following review of the protocol by the Advarra Institutional Review Board (Pro00067856). Written informed consent was obtained from all study subjects.
